Viking Therapeutics (NASDAQ: VKTX) Starts Presentation at LD Micro 2017 Invitational
Viking Therapeutics (NASDAQ: VKTX) is a clinical-stage biopharmaceutical company that focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program is VK5211, an orally available drug candidate, which is in a phase II clinical trials for acute rehabilitation following non-elective hip fracture surgery. The company also develops VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid beta receptor for the treatment of hypercholesterolemia and fatty liver disease, as well as for the orphan indication glycogen storage disease Type Ia, and VK0214 for the treatment of orphan indication X-linked adrenoleukodystrophy. For more information,…







